# Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer

> **NCT00364754** · PHASE1 · COMPLETED · sponsor: **YM BioSciences** · enrollment: 28 (actual)

## Conditions studied

- Metastatic/Recurrent Breast Cancer

## Interventions

- **DRUG:** Tesmilifene (YMB 1002)

## Key facts

- **NCT ID:** NCT00364754
- **Lead sponsor:** YM BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364754, "Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00364754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*